VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

ICLE 2022 | Improving immune-imaging tools to assess cancer immunotherapies

Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, discusses challenges in utilizing non-invasive immune-imaging tools as predictive and surrogate markers. Whilst assessing minimal disease residue (MRD) in multiple myeloma is well established, imaging T-cell activity and subsequent tumor regression is limited for immunotherapies. Measuring CD8 activity without T-cell depletion is important and fragmented antibodies can examine the extent of T-cell infiltration in the tumor. Prof. Krackhard also describes using these imaging techniques to detect tumor flare reaction (TFR) and pseudoprogression, which can normally hamper response evaluation. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022